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Pentoxifylline has several actions that improve
blood rheology and tissue perfusion and may there-
fore potentially be applicable to diabetic neuropathy.
The aims of this study were to ascertain whether 2
weeks of treatment with pentoxifylline could correct
nerve conduction velocity and blood flow deficits in
6-week streptozotocin-diabetic rats and to examine
whether the effects were blocked by co-treatment
with the cyclooxygenase inhibitor, flurbiprofen, or
the nitric oxide synthase inhibitor, NG-nitro-L-argi
nine. Diabetic deficits in sciatic motor and saphen-
ous sensory nerve conduction velocity were 56.5%
and 69.8% corrected, respectively, with pentoxifyl-
line treatment. Sciatic endoneurial blood flow was
approximately halved by diabetes and this deficit
was 50.4% corrected by pentoxifylline. Flurbiprofen
co-treatment markedly attenuated these actions of
pentoxifylline on nerve conduction and blood flow
whereas
G N-nitro-L-arginine was without effect.
Thus, pentoxifylline treatment confers neurovascu-
lar ben.efits in experimental diabetic neuropathy,
which are linked at least in part to cyclooxygenase-
mediated metabolism.
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INTRODUCTION
The early neuropathic changes in experimental
diabetes, such as diminished conduction velo-
city (NCV), are believed to be largely attribu-
table to a reduction in nerve perfusion (Tuck
et al., 1984; Cameron et al., 1991). Parallels
may be drawn with reduced sural nerve blood
flow and the presence of endoneurial hypoxia
in neuropathic patients (Tesfaye et al., 1994).
Several vasodilators have been identified that
partially prevent or correct nerve dysfunction
in diabetic rats (Cameron et al., 1994a), and
patients (Tesfaye et al., 1994), presumably by
improving perfusion and oxygenation. Major
contributions to impaired nerve blood flow are
made by decreased vasa nervorum prostacyclin
and nitric oxide (NO) production or action, and
elevated vasoconstrictor activity (Ward et al.,
1989; Kihara and Low, 1995; Maxfield et al.,
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1995, 1997; Cameron and Cotter, 1996a). In turn,
these changes result from metabolic conse-
quences of hyperglycemia, including increased
polyol pathway, elevated production of re-
active oxygen species, advanced glycation
and protein kinase C activation (Cameron et al.,
1994a, 1994b, 1996; Cameron and Cotter, 1996b;
Cameron et al., 1999; Sima and Sugimoto, 1999).
Diabetes also causes elevated blood viscos-
ity, decreased red cell deformability, increas-
ed platelet activation, a prothrombotic state,
and phagocyte activation that may contribute
to reduced nerve perfusion (Simpson, 1988;
Ceriello, 1993).
Pentoxifylline is a methylxanthine deriva-
tive possessing hemorheological actions that im-
prove the microcirculation (Ward and Clissold,
1987). It is a phosphodiesterase inhibitor that
can cause vasodilation in some vessels by endo-
thelium-dependent and independent mecha-
nisms (Hansen, 1994; Kaputlu and Sadan, 1994).
Pentoxifylline also inhibits production of plate-
let activating factor, reduces platelet aggrega-
tion, increases red cell membrane fluidity,
and reduces the production of inflammatory
cytokines, particularly tumor necrosis factor, by
phagocytes and vascular endothelium (Adams
et al., 1995; Ambrus et al., 1995; Bernard et al.,
1995; Mandell, 1995). Thus, pentoxifylline has
vascular and rheological actions that may coun-
teract some of the changes in diabetes that con-
tribute to nerve dysfunction. The aim of this
study was to determine whether pentoxifylline
treatment corrects NCV and perfusion deficits
in diabetic rats. As some putative actions of
pentoxifylline involve correction or potentia-
tion of the effects of prostacyclin and NO sys-
tems, the outcomes of co-treatment with the
cyclooxygenase inhibitor, flurbiprofen, or the
NO synthase inhibitor, N-nitro-L-arginine,
were examined to further elucidate underlying
mechanisms. Preliminary data were presented at
a meeting of the International Diabetes Federa-
tion (Cotter et al., 1997).
MATERIALS AND METHODS
Male Sprague-Dawley rats, 19 weeks of age at
the start of the experiment, were used. Diabetes
was induced by intraperitoneal injection (40-
45mg kg-1) of streptozotocin (Zeneca, Maccles-
field, Cheshire, UK) freshly made up in sterile
saline. Diabetes was verified 24 h later by esti-
mating hyperglycemia and glycosuria (Visidex
II and Diastix; Ames, Slough, UK). Rats were test-
ed weekly, and weighed daily; they were rejected
if blood glucose was < 20mM or if they showed
a consistent increase in body weight over 3
days. Samples for plasma glucose measurement
(GOD-Perid method; Boehringer, Mannheim,
Germany) were taken from the tail vein before
or from a carotid cannula after final experiments.
Experimental groups comprised non-diabetic
onset control rats (n=20), 8-week untreated
diabetic rats (n 20), and 6-week untreated dia-
betic groups treated for a further 2 weeks with
pentoxifylline (Sigma, Poole, Dorset, UK) at a
dose of 40mgkg
-1 day
-1 p.o. (n 26) or pentoxi-
fylline + N-nitro-L-arginine (Sigma; 10mgkg
-1
day-1, added to the drinking water) (n 22) or
pentoxifylline + flurbiprofen (Sigma; 5mgkg
-1
day-1, added to the drinking water) (n=20).
Doses of N-nitro-L-arginine and flurbiprofen
were chosen to have modest effects on neuro-
vascular function in non-diabetic rats, but to be
effective in blocking effects of certain inter-
ventions in diabetic rats, including aldose re-
ductase inhibition and a;-6 essential fatty acid
treatment (Cameron et al., 1996, 1993). Separate
groups of rats were used to assess motor and
sensory NCV (n 10-16), and sciatic nerve per-
fusion (n 9-10).
At the end of the treatment period, rats were
anesthetized with urethane (Sigma; 1-1.5mg
kg-1), or for the nerve perfusion experiments
with thiobutabarbital (Zeneca; 50-100mg kg-1),
by intraperitoneal injection. The trachea was
cannulated for artificial ventilation. A carotid
cannula was used to monitor mean systemicPENTOXIFYLLINE AND NEUROVASCULAR DYSFUNCTION 51
blood pressure in rats undergoing blood flow
measurement. Motor NCV was assessed be-
tween the sciatic notch and the knee in the
nerve branch innervating the tibialis anterior
muscle as previously described (Cameron et al.,
1989). This is representative of the whole sciatic
nerve in terms of susceptibility to diabetes and
treatment effects. Sensory NCV was measured
in saphenous nerve between the groin and the
ankle as previously described (Cameron et al.,
1989). Rectal and nerve temperatures were moni-
tored, and kept between 36.5 and 37.5C.
Sciatic endoneurial blood flow was measured
by microelectrode polarography and hydrogen
clearance as previously described (Cameron
et al., 1991). Briefly, the core temperature of the
rat was monitored and kept between 37 and
38C, using a rectal probe and radiant heat. The
skin around the sciatic nerve incision was su-
tured to a metal ring and used to form a pool,
which was filled with mineral oil. Pool tempera-
ture was maintained between 35 and 37C by
radiant heat during blood flow measurements.
Rats were given neuromuscular blockade us-
ing d-tubocurarine (Sigma, 2mg kg
-1 via the
carotid cannula) and we.re artificially ventilated.
The level of anesthesia was monitored by ob-
serving blood pressure reactions to manipula-
tions and supplementary anaesthetic was given
as necessary. A glass-insulated platinum micro-
electrode was inserted into the middle portion
of the sciatic .nerve, above its trifurcation, and
polarized at 0.25 V with respect to a subcutane-
ous reference electrode. 10% H2 was added to
the inspired gas, the proportions of 02 and N2
being adjusted to 20% and 70% respectively.
When the H2 current recorded by the electrode
had stabilized, indicating equilibrium with ar-
terial blood, the H2 supply was shut off and N2
delivery was increased appropriately. The H2
clearance curve was recorded until baseline
values were reached, the latter being defined as
no systematic decline in electrode current over
5min. This procedure was then repeated at
another site of the sciatic nerve. After the ex-
periment, clearance curves were digitized and
mono-exponential or bi-exponential curves were
fitted to the data by computer using non-linear
regression software that employs the Marquardt
algorithm and the least squares method for opti-
mizing goodness-of-fit (Prism, Graphpad, San
Diego, CA, USA). The slow exponent was tak-
en to reflect nutritive (capillary) flow (Day et al.,
1989). Vascular conductance was calculated by
dividing flow by the mean arterial blood pres-
sure during the recording period. The average
of the two determinations was taken as repre-
sentative for all measures of sciatic endoneurial
blood flow.
Statistical Analysis
Data are presented as group means + SEM. They
were given Bartlett’s test for homogeneity of
variances, followed by log transformation where
appropriate (nutritive vascular conductance and
composite blood flow) before being subjected
to one-way analysis of variance. When over-
all significance (P < 0.05) was attained, between-
group differences were established by post hoc
analysis using the Student-Newman-Keuls test
which is corrected for multiple comparisons.
RESULTS
Diabetic rats showed an approximately 5-fold
increase in plasma glucose concentration (Tab. I)
compared to controls and had an approximate-
ly 27% body weight loss over the 8-week
experimental period. These parameters were
not significantly altered by pentoxifylline, Nc-
nitro-L-arginine or flurbiprofen treatment.
Sciatic motor NCV (Fig. 1A) was 20.6 4-0.9%
reduced by 8 weeks of diabetes. Pentoxifyl-
line treatment for the last 2 weeks corrected this
NCV deficit by 56.5 4- 7.7% (P < 0.001), although
conduction remained reduced compared to the52 H. FLINT et al.
TABLE Body weights and plasma glucose concentrations
Group n Body weight(g) Glucose (mM)
Non-diabetic 20 435 4- 5 8.3 4- 0.5
Diabetic 20 313 4- 9 45.0 4-1.8
+ pentoxifylline 26 334 4- 7 39.8 4-1.4
+ pentoxifylline+ N-nitro-L-arginine 22 310 4- 7 40.0 4-1.4
+ pentoxifylline+ flurbiprofen 20 314 4- 8 41.4 4-1.4
Data are mean 4- SEM.
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FIGURE 1 Effects of diabetes and treatment with pentoxifylline, alone and in combination with nitric oxide synthase or
cyclooxygenase inhibition, on (A) sciatic nerve motor and (B) saphenous nerve sensory conduction velocity. N, non-diabetic
controls (n 10); D, 8-week diabetic controls (n 10); DP, 8-week diabetic rats treated for the last 2 weeks with 40mg kg
-1 day
-1
pentoxifylline (n 16); DPN, 8-week diabetic rats treated for 2 weeks with pentoxifylline and 10mg kg
-1 day-
N-nitro-L-argi
nine (n 13); DPF, 8-week diabetic rats treated for 2 weeks with pentoxifylline and 5mg kg
-1 day
-1 flurbiprofen (n= 11). Data
are mean 4- SEM.
non-diabetic group (P<0.001). Co-treatment
with N-nitro-L-arginine did not significantly
alter the effect of pentoxifylline (55.44-4.6%
correction; P <0.001 versus diabetic and non-
diabetic groups). In contrast, flurbiprofen attenu-
ated pentoxifylline’s action by 52.94-12.6%
(P < 0.01), although the resultant motorNCV val-
ue remained significantly (P < 0.05) greater than
that of the diabetic control group.
Sensory saphenous NCV (Fig. 1B) was
12.1 4-1.9% (P < 0.001) reduced by untreated dia-
betes. This was completely corrected by pentoxi-
fylline treatment (P <0.01). N-nitro-L-arginine
co-treatment was without effect on pentoxifyl-
line’s action; NCV was in the non-diabetic range.
However, with flurbiprofen co-treatment, NCV
remained at the untreated diabetic level (P < 0.01
versus pentoxifylline treatment alone).
A 48.44-2.2% diabetic deficit (P<0.001) in
sciatic nutritive endoneurial blood flow (Fig. 2A)
was partially (44.7 4- 8.4%; P <0.001) corrected
by pentoxifylline treatment, although a signifi-
cant deficit remained compared to the non-
diabetic control group (P <0.001). The effect of
pentoxifylline was not significantly attenuated
by N -nitro-L-arginine co-treatment, but it was
84.0 4- 4.0% diminished (P < 0.05) by flurbiprofen
such that the resultant value was in the upper
diabetic range.
Mean systemic blood pressure (Fig. 2B)
tended to be reduced in the diabetic groups,
although this was only statistically signifi-
cant (P<0.05) for untreated diabetes. Within
the diabetic groups, the highest pressures were
recorded with N -nitro-L-arginine co-treat-
ment. As sciatic vasa nervorum does not showPENTOXIFYLLINE AND NEUROVASCULAR DYSFUNCTION 53
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FIGURE 2 Effects of diabetes and treatment with pentoxi-
fylline, alone and in combination with nitric oxide synthase
or cyclooxygenase inhibition, on (A) sciatic nutritive endo-
neurial blood flow, (B) mean systemic blood pressure and (C)
nutritive endoneurial vascular conductance (VC). N, non-
diabetic controls (n 10); D, 8-week diabetic controls (n 10);
DP, 8-week diabetic rats treated for the last 2 weeks with
40mgkg
-1 day
-1 pentoxifylline (n= 10); DPN, 8-week dia-
betic rats treated for 2 weeks with pentoxifylline and 10mg
kg
-1 day-1NC-nitro-L-arginine (n =9); DPF, 8-week diabetic
rats treated for 2 weeks with pentoxifylline and 5mgkg
-1
day
-1 flurbiprofen (n 9). Data are mean 4- SEM.
conductance deficit (P <0.001) was 58.94-15.1%
(P < 0.01) corrected by pentoxifylline treatment.
This was 29.8% and 66.9% attenuated by Nc-
nitro-L-arginine and flurbiprofen co-treatments
respectively, although in neither case did the
effect reach statistical significance. While conduc-
tances for all treated diabetic rats remained be-
low (P <0.01) that of the non-diabetic group,
the value for the pentoxifylline+NC-nitro-L-argi
nine group exceeded that of untreated diabetes
(P < 0.05) whereas this was not the case for pen-
toxifylline + flurbiprofen treated rats.
The hydrogen clearance microelectrode po-
larography method records both nutritive (capil-
lary) endoneurial and non-nutritive (large vessel
and arterio-venous anastomotic)flow (Cameron
et al., 1996; Day et al., 1989). The weighted sum of
these components describes total or composite
endoneurial flow (Fig. 3A). This was 58.3 4- 3.3%
(P < 0.001) reduced by diabetes and 55.6 4-14.0%
(P < 0.01) corrected by pentoxifylline treatment,
the resultant value being not significantly differ-
ent from that of the non-diabetic control group.
Both NG-nitro-L-arginine (P < 0.01) and flurbipro-
fen (P <0.001) co-treatments completely attenu-
ated the effects of pentoxifylline on composite
endoneurial blood flow. Similar effects were
seen for composite vascular conductance (Fig.
3B), the value for pentoxifylline treatment alone
being in the non-diabetic range whereas those
for NG-nitro-L-arginine and flurbiprofen co-treat-
ment were in the diabetic range. The percentage
of hydrogen clearance carried by nutritive flow
(Fig. 3C) was not significantly affected by diab-
etes. However, with pentoxifylline treatment
alone, this was approximately halved compared
to all the other groups (P < 0.05).
DISCUSSION
appreciable pressure autoregulation (Day et al.,
1989) flow results are expressed as vascular
conductance (Fig. 2C) to take account of these
pressure differences. A 40.04-2.3% diabetic
The data show that pentoxifylline treatment
partially corrected sciatic motor and comple-
tely corrected saphenous sensory NCV. Great-
er responsiveness of sensory conduction deficits54 H. FLINT et al.
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FIGURE 3 Effects of diabetes and treatment with pentoxi-
fylline, alone and in combination with nitric oxide synthase
or cyclooxygenase inhibition, on (A) sciatic composite endo-
neurial blood flow, (B) composite vascular conductance (VC)
and (C) the proportion of endoneurial hydrogen clearance
carried by the nutritive flow component. Group details are
given in the legend to Figure 2. Data are mean + SEM.
to several unrelated treatments, including al-
dose reductase inhibitors, a vasodilator and an
antioxidant, has been previously observed in
diabetic rats (Cameron et al,, 1994b, 1989, 1994c;
Nagamatsu et al., 1995). Pentoxifylline can act
as a phosphodiesterase inhibitor, and a recent
study showed that 4 weeks of treatment with a
high dose of the type III (cAMP) phophodiester-
ase inhibitor, cilostazol, prevented reductions
in motor NCV by 30% for tibial and 60%
for caudal nerve in diabetic rats (Kihara et al.,
1995). That degree of protection is in reasonable
agreement with the magnitude of correction of
proximal sciatic nerve motor NCV seen with
pentoxifylline treatment in this study.
Sciatic endoneurial nutritive blood flow was
increased by pentoxifylline, roughly in propor-
tion to the effect on motor conduction. This pro-
vides further support for a vascular etiology of
nerve dysfunction in diabetes. High-dose cilosta-
zol treatment approximately halved the nutri-
tive endoneurial blood flow deficit in diabetic
rats (Kihara et al., 1995). While pentoxifylline,
like cilostazol, has phosphodiesterase inhibitor
properties, it also has several other actions that
may be relevant for diabetic neuropathy. Thus,
pentoxifylline reduces cytokine formation by
phagocytes and blood vessels, particularly that
of tumor necrosis factor (Bernard et al., 1995;
Mandell, 1995). The latter can evoke several de-
leterious vascular changes in diabetes relevant
to vasa nervorum dysfunction. Tumor necrosis
factor can activate protein kinase C (Deisher
et al., 1993) and stimulate nuclear factor B in
endothelial cells (Tozawa et al., 1995). This tran-
scription factor causes several effects includ-
ing elevated endothelin-1 synthesis, decreased
NO production, and altered expression of ad-
hesion molecules and increased cell-endothe-
lium interaction (Collins, 1993; Rubanyi and
Polokoff, 1994; Limb et al., 1996; Bierhaus et al.,
1997). Circulating levels of tumor necrosis factor
are elevated in diabetic rats, and this may be pre-
vented by treatment with N-acetyl-L-cysteine,
which also restores endothelial function, endo-
neurial blood flow and NCV (Archibald et al.,
1996; Love et al., 1996a; Sagara et al., 1996).
Pentoxifylline has also been identified as a
scavenger of hydroxyl (but not superoxide)PENTOXIFYLLINE AND NEUROVASCULAR DYSFUNCTION 55
radicals in vitro (Freitas and Filipe, 1995) over a
concentration range relevant to the dose used in
this in vivo study. The production of reactive
oxygen species is increased by diabetes and en-
dogenous antioxidant defense mechanisms in
nerve are compromised (Cameron et al., 1999;
Nagamatsu et al., 1995; Nickander et al., 1994).
Hydroxyl radicals are short-lived but highly
reactive and can be formed by transition met-
al catalyzed processes such as the Fenton reac-
tion, which are relevant to diabetes (Cameron
and Cotter, 1995a). Another source of hydro-
xyl radicals is the breakdown of peroxynitrite
(Beckman et al., 1990), formed from the reac-
tion between NO and superoxide. This process
probably contributes to endothelial dysfunc-
tion (Pieper et al., 1993) and neurovascular defi-
cits (Kihara and Low, 1995; Maxfield et al., 1997)
in experimental diabetes. While there have
not been any reports on the effects of speci-
fic hydroxyl radical scavengers on nerve func-
tion, transition metal chelators are effective in
restoring nerve blood flow, NCV and regenera-
tive capacity in experimental models of diabetic
neuropathy (Cameron and Cotter, 1995a; Love
et al., 1996b).
The platelet anti-aggregatory effect of pentox-
ifylline is likely to depend on inhibition of plate-
let phosphodiesterase, allowing elevated cAMP
levels to inhibit the formation of thromboxane
A2 (Ward and Clissold, 1987). However, this
requires relatively high doses that may not have
been attained in this in vivo experiment. In ad-
dition, use of specific thromboxane A2 recep-
tor/thromboxane synthase antagonist treatment
only has a modest effect ( 16% correction) on
motor NCV in diabetic rats (Dines et al., 1996).
Although the rheological/anti-platelet actions of
pentoxifylline may be contributory; alone they
are probably not sufficient to account for the
effects on neurovascular function in diabetic
rats. The improvements in NCV and blood flow
with pentoxifylline were attenuated by co-treat-
ment with the cyclooxygenase inhibitor, flurbi-
profen, but not by NO synthase inhibition. This
suggests that the major action of pentoxifyl-
line in these experiments depended upon cy-
clooxygenase products rather than NO. A vasa
nervorum prostacyclin deficit contributes to
reduced nerve blood flow in diabetic rats
(Ward et al., 1989). This appears to be caused
primarily by a deficit in substrate availability,
since it is corrected by treatment with 0;-6 es-
sential fatty acids such as -y-linolenic or ar-
achidonic acid (Cameron and Cotter, 1999).
Prostacyclin promotes vascular smooth muscle
relaxation via a cAMP-dependent mechanism.
It is plausible, therefore, that a major effect of
pentoxifylline is to reduce cAMP breakdown
via a phosphodiesterase inhibitor action, thus
potentiating the vasorelaxant effects of endo-
genous prostacyclin. This would at least partially
compensate for reduced vasa nervorum prosta-
cyclin synthesis, and is in accord with the fin-
ding that prostacyclin analogs correct NCV and
blood flow deficits in diabetic rats (Cotter et al.,
1993; Hotta et al., 1996).
The resistance of pentoxifylline treatment to
NO synthase inhibition sets it apart from sever-
al other drugs that improve endoneurial perfu-
sion and NCV in diabetic rats. These include
aldose reductase inhibitors (Cameron et al., 1996;
Stevens et al., 1994), aminoguanidine (Cameron
and Cotter, 1996b), antioxidants (Cameron and
Cotter, 1995b) and protein kinase C inhibitors
(Cameron et al., 1999). These drugs all attenu-
ate the development of defective NO-mediated
endothelium-dependent vasorelaxation in diabe-
tes (Cameron and Cotter, 1994a; Archibald et al.,
1996). However, the effects of aldose reductase
inhibitors are also opposed by flurbiprofen,
perhaps because they moderately improve en-
dothelial production of prostacyclin and other
prostanoids and act on the NO system (Law and
King, 1990; Wakasugi et al., 1991).
Pentoxifylline treatment caused a change in
the pattern of endoneurial blood flow in dia-
betic rats. While there was an overall increase in
flow, including the nutritive capillary compo-
nent, non-nutritive flow was emphasized. This56 H. FLINT et al.
suggests that there was a relative increase in arte-
riovenous shunting and is compatible with the
notion that pentoxifylline potentiates the vas-
cular actions of prostanoids. Evening primrose
oil treatment, that supplies a high dose of
linolenic acid promoting prostanoid synthesis,
increases nerve blood flow and has a particu-
larly marked action on the non-nutritive compo-
nent (Cameron and Cotter, 1994b). Conversely,
flurbiprofen treatment of diabetic rats had the
opposite effect, reducing non-nutritive more
than the nutritive flow (Cameron et al., 1996).
On the other hand, aldose reductase inhibitors
favor nutritive perfusion (Cameron et al., 1994b),
although they can increase prostanoid produc-
tion. It is possible that the different drug effects
on endoneurial blood flow depends on how they
alter the balance between prostanoid and NO
actions on vasa nervorum.
In conclusion, pentoxifylline partially cor-
rected the endoneurial blood flow deficit, and
improved NCV in diabetic rats. These neuro-
vascular effects probably depend in large part
on a potentiation of prostanoid-mediated vaso-
dilator and rheological actions. Pentoxifylline is
used in the treatment of peripheral vascular dis-
ease (Ward and Clissold, 1987), and it is possible
that it may also prove useful in the treatment
of diabetic neuropathy.
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